Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: Case report and review of the literature

Transplant Infectious Disease

Volumn 14, Issue 5, 2012, Pages

  Levy, D T ^a   Steed, M E ^b   Rybak, M J ^c   Guo, Y ^a   Gialanella, P ^a   Hanau, L ^a   Muggia, V ^a   Ostrowsky, B ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Daptomycin non susceptibility; Heart transplant; Infection; Left ventricular assist device; MRSA

Indexed keywords

COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LINEZOLID; RIFAMPICIN; TELAVANCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CASE REPORT; DEVICE INFECTION; DEVICE REMOVAL; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; LEFT VENTRICULAR ASSIST DEVICE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HEART-ASSIST DEVICES; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84867658546     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00775.x     Document Type: Article

References (74)

1. Schaffer JM, Allen JG, Weiss ES, et al. Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2011; 30 (2): 164-174.
2. Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg 2010; 90 (4): 1270-1277.
3. Holman WL, Park SJ, Long JW, et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 2004; 23 (12): 1359-1365.
4. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 2001; 72 (3): 725-730.
5. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 2005; 40 (8): 1108-1115.
6. Holman WL, Kirklin JK, Naftel DC, et al. Infection after implantation of pulsatile mechanical circulatory support devices. J Thorac Cardiovasc Surg 2010; 139 (6): 1632-1636.
7. Fischer SA, Trenholme GM, Costanzo MR, Piccione W. Infectious complications in left ventricular assist device recipients. Clin Infect Dis 1997; 24 (1): 18-23.
8. Jacobs S, Huprikar S, Pinney S, Anelechi A, Calfee D, Patel G. Increased Prevalence of Multidrug-Resistant Organisms in Patients with Left Ventricular Assist Devices. 48th Annual Meeting of Infectious Diseases Society of America. Vancouver, BC. October 2010.
9. Beiras-Fernandez A, Kur F, Kiefer S, et al. Multidrug-resistant gram-positive infections in patients with ventricular assist devices: the role of daptomycin. Transplant Proc 2009; 41 (6): 2589-2591.
10. Sinha P, Chen JM, Flannery M, Scully BE, Oz MC, Edwards NM. Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 2000; 102 (19 Suppl 3): III194-199.
11. Argenziano M, Catanese KA, Moazami N, et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 1997; 16 (8): 822-831.
12. Morgan JA, Park Y, Oz MC, Naka Y. Device related infections while on left ventricular assist device support do not adversely impact bridging to transplant or posttransplant survival. ASAIO J 2003; 49 (6): 748-750.
13. Schulman AR, Martens TP, Russo MJ, et al. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant 2009; 28 (3): 237-242.
14. Herrmann M, Weyand M, Greshake B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997; 95 (4): 814-817.
15. McGee EC Jr, Cotts W, Tambur AR, et al. Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. J Heart Lung Transplant 2008; 27 (5): 568-571.
16. Poston RS, Husain S, Sorce D, et al. LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant 2003; 22 (8): 914-921.
17. Prendergast TW, Todd BA, Beyer AJ 3rd, et al. Management of left ventricular assist device infection with heart transplantation. Ann Thorac Surg 1997; 64 (1): 142-147.
18. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient-a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30 (5): 603-610.
19. Twele L, Moyen E, Zhang K, Dalton B, Church D, Conly J. Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy. Can J Infect Dis Med Microbiol 2010; 21 (2): 89-93.
20. Hirschwerk D, Ginocchio CC, Bythrow M, Condon S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2006; 27 (3): 315-317.
21. Paez AS, Brown RB, Wilk PA, Bourgeault RG, Rauch CA. Rapid loss of daptomycin susceptibility in methicillin-resistant Staphylococcus aureus blood culture isolates from an infective endocarditis patient. Infect Dis Clin Pract 2006; 14: 322-324.
22. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44 (2): 655-656.
23. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43 (10): 5285-5287.
24. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40 (7): 1058-1060.
25. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44 (2): 595-597.
26. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 2008; 57 (Pt 8): 1036-1038.
27. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005; 43 (10): 5384-5387.
28. Cunha BA, Pherez FM. Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE). Eur J Clin Microbiol Infect Dis 2009; 28 (7): 831-833.
29. Shipton LK, Pillai S, Gold H, et al. Experience with daptomycin in Staphylococcus bone and joint infections. Case series and emergence of nonsusceptibility. Infect Dis Clin Pract 2007; 15 (5): 324-329.
30. Amchentsev A, Devakonda A, Abraham T, et al. Daptomycin resistance in vancomycin-intermediate Staphylococcus aureus isolate. Internet J Infect Dis 2009; 7 (2): DOI: 10.5580/10f4.
31. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355 (7): 653-665.
32. Kirby A, Mohandas K, Broughton C, et al. In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with methicillin-resistant S. aureus endocarditis. J Med Microbiol 2009; 58 (Pt 3): 376-380.
33. Lee CH, Wang MC, Huang IW, Chen FJ, Lauderdale TL. Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment. Antimicrob Agents Chemother 2010; 54 (9): 4038-4040.
34. Mariani PG, Sader HS, Jones RN. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58 (2): 481-483.
35. Tenover FC, Sinner SW, Segal RE, et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33 (6): 564-568.
36. Sakoulas G, Rose W, Rybak MJ, et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol 2008; 46 (1): 220-224.
37. Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2008; 27 (6): 433-437.
38. Schmid C, Schneider M, Etz C, Scheld HH. Heart transplantation in a patient with a left ventricular assist device and methicillin-resistant Staphylococcus aureus infection. Ann Thorac Surg 2004; 78 (5): 1820-1822.
39. Ahmad NM, Rojtman AD. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ann Pharmacother 2010; 44 (5): 918-921.
40. Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42 (12): e108-e110.
41. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria that Grow Aerobically; Approved Standard. (8th edn.) Wayne, PA: CLSI, 2009.
42. Zhang K, McClure JA, Elsyed S, Louie T, Conly JM. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I-V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5026-5033.
43. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128-1132.
44. Strommenger B, Braulke C, Pasemann B, Schmidt C, Witte W. Multiplex PCR for rapid detection of Staphylococcus aureus isolates suspected to represent community acquired strains. J Clin Microbiol 2008; 46: 582-587.
45. Lina G, Boutite F, Tristan M, Bes M, Etienne J, Vandenesch F. Bacterial competition for human nasal cavity colonization: role of staphylococcal agr alleles. Appl Environ Microbiol 2003; 69: 18-23.
46. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49 (7): 2687-2692.
47. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38 (12): 1700-1705.
48. Rose WE, Rybak MJ, Tsuji BT, Kaatz GW, Sakoulas G. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother 2007; 59 (6): 1190-1193.
49. Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190 (6): 1140-1149.
50. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199 (5): 619-624.
51. Bae IG, Federspiel JJ, Miro JM, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200 (9): 1355-1366.
52. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacteria strain typing. J Clin Microbiol 1995; 33: 2233-2239.
53. Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin Microbiol Infect 2009; 15 (Suppl 6): 11-16.
54. Kirkpatrick P, Raja A, LaBonte J, Lebbos J. Daptomycin. Nat Rev Drug Discov 2003; 2 (12): 943-944.
55. Micklefield J. Daptomycin structure and mechanism of action revealed. Chem Biol 2004; 11 (7): 887-888.
56. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38 (12): 1673-1681.
57. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults. Summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29 (11): 1275-1279.
58. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. M100-S20, vol 30, no. 1. Wayne, PA: CLSI, 2010.
59. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50 (3): 1079-1082.
60. Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother 2009; 53 (8): 3190-3196.
61. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9 (10): 617-624.
62. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50 (6): 2137-2145.
63. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52 (1): 269-278.
64. Yang SJ, Xiong YQ, Dunman PM, et al. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 2009; 53 (6): 2636-2637.
65. Yang SJ, Kreiswirth BN, Sakoulas G, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 2009; 200 (12): 1916-1920.
66. Mishra NN, Yang SJ, Sawa A, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53 (6): 2312-2318.
67. Kaatz GW, Lundstrom TS, Seo SM. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006; 28 (4): 280-287.
68. Kilelee E, Pokorny A, Yeaman MR, Bayer AS. Lysyl-phosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance. Antimicrob Agents Chemother 2010; 54 (10): 4476-4479.
69. Boyle-Vavra S, Jones M, Gourley BL, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 2011; 55 (5): 2018-2025.
70. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, Eliopoulos GM. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 2007; 51 (6): 2223-2225.
71. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52 (3): e18-e55.
72. Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis 2008; 61 (2): 235-239.
73. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007; 57 (4): 459-465.
74. Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis 2011; 70 (3): 412-416.